TGM3

Across TCGA pan-cancer cohorts, TGM3 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated TGM3 data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in brain lower grade glioma (LGG), where higher TGM3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TGM3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

LGG, LUSC, and BLCA are the cancer types where TGM3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	OS	Median	All	0.133	0.811	<.001	12	view →
LUSC	DFS	Median	II,III,IV	0.210	0.599	.007	12	view →
BLCA	DFS	Median	All	0.153	0.598	.013	9	view →
GBM	OS	Median	All	0.005	0.416	<.001	6	view →
SCLC	DFS	Median	All	0.285	0.587	.013	6	view →
UCEC	DFS	Median	II,III,IV	0.922	0.438	.030	6	view →
ESCA	DFS	Median	All	0.146	0.533	.046	3	view →
SKCM	OS	Median	II,III,IV	0.870	0.719	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

TGM3–LGG (OS)

Open the LGG breakdown →